The FDA is proposing to remove oral phenylephrine, an ingredient in cold and cough syrups, due to lack of efficacy. Meanwhile, Eisai’s sales growth for Alzheimer’s drug Leqembi has been less than expected, with challenges in regulatory approval and reimbursement decisions. Phenylephrine is a common ingredient in OTC medicines, while Leqembi sales have not met initial projections, with regulators expressing concerns about efficacy and side effects. The FDA decision is limited to oral phenylephrine, not the nasal spray form. Both cases highlight challenges in drug effectiveness and market uptake, impacting both consumers and pharmaceutical companies.
Source link
We’re reading about a cold medicine ban, Alzheimer’s drug sales
